Stock Analiz

Artiva Biotherapeutics, Inc. ARTV

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2024 · data as of November 13, 2026

$4.01Market cap $198M
Open the interactive analysis →

Artiva Biotherapeutics, Inc. (ARTV) is a healthcare company listed in the US with a market value of about $198M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -46%.

About Artiva Biotherapeutics

Artiva Biotherapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2024. It was profitable in 0 of the last 3 years in our data.

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-43.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-100.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-13065.4%
ROIC (5-yr avg.)-46.1%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal year202520242023
Revenue$0$251000$33M
Net income-$84M-$65M-$29M
Free cash flow-$79M-$56M-$51M
EPS (diluted)$-3.43$-5.81$-35.78
Net margin—-26045.0%-85.8%
ROIC-58.7%-33.5%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Artiva Biotherapeutics pay a dividend?

Not currently.

Is Artiva Biotherapeutics a good stock to buy?

We do not give buy or sell advice. Artiva Biotherapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.